IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v7y2016i1d10.1038_ncomms12308.html
   My bibliography  Save this article

The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia

Author

Listed:
  • Thomas M. Ashton

    (CRUK/MRC Oxford Institute for Radiation Oncology)

  • Emmanouil Fokas

    (CRUK/MRC Oxford Institute for Radiation Oncology)

  • Leoni A. Kunz-Schughart

    (CRUK/MRC Oxford Institute for Radiation Oncology
    OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden, and Helmholtz-Zentrum Dresden–Rossendorf, Institute of Radiooncology)

  • Lisa K. Folkes

    (CRUK/MRC Oxford Institute for Radiation Oncology)

  • Selvakumar Anbalagan

    (CRUK/MRC Oxford Institute for Radiation Oncology)

  • Melanie Huether

    (OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden, and Helmholtz-Zentrum Dresden–Rossendorf, Institute of Radiooncology)

  • Catherine J. Kelly

    (CRUK/MRC Oxford Institute for Radiation Oncology)

  • Giacomo Pirovano

    (CRUK/MRC Oxford Institute for Radiation Oncology)

  • Francesca M. Buffa

    (CRUK/MRC Oxford Institute for Radiation Oncology)

  • Ester M. Hammond

    (CRUK/MRC Oxford Institute for Radiation Oncology)

  • Michael Stratford

    (CRUK/MRC Oxford Institute for Radiation Oncology)

  • Ruth J. Muschel

    (CRUK/MRC Oxford Institute for Radiation Oncology)

  • Geoff S. Higgins

    (CRUK/MRC Oxford Institute for Radiation Oncology)

  • William Gillies McKenna

    (CRUK/MRC Oxford Institute for Radiation Oncology)

Abstract

Tumour hypoxia renders cancer cells resistant to cancer therapy, resulting in markedly worse clinical outcomes. To find clinical candidate compounds that reduce hypoxia in tumours, we conduct a high-throughput screen for oxygen consumption rate (OCR) reduction and identify a number of drugs with this property. For this study we focus on the anti-malarial, atovaquone. Atovaquone rapidly decreases the OCR by more than 80% in a wide range of cancer cell lines at pharmacological concentrations. In addition, atovaquone eradicates hypoxia in FaDu, HCT116 and H1299 spheroids. Similarly, it reduces hypoxia in FaDu and HCT116 xenografts in nude mice, and causes a significant tumour growth delay when combined with radiation. Atovaquone is a ubiquinone analogue, and decreases the OCR by inhibiting mitochondrial complex III. We are now undertaking clinical studies to assess whether atovaquone reduces tumour hypoxia in patients, thereby increasing the efficacy of radiotherapy.

Suggested Citation

  • Thomas M. Ashton & Emmanouil Fokas & Leoni A. Kunz-Schughart & Lisa K. Folkes & Selvakumar Anbalagan & Melanie Huether & Catherine J. Kelly & Giacomo Pirovano & Francesca M. Buffa & Ester M. Hammond &, 2016. "The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia," Nature Communications, Nature, vol. 7(1), pages 1-13, November.
    • Handle: RePEc:nat:natcom:v:7:y:2016:i:1:d:10.1038_ncomms12308
    DOI: 10.1038/ncomms12308
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/ncomms12308
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/ncomms12308?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:7:y:2016:i:1:d:10.1038_ncomms12308. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.